Last reviewed · How we verify
Week 48
At a glance
| Generic name | Week 48 |
|---|---|
| Sponsor | University Hospital, Ghent |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) (PHASE3)
- A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection (PHASE2)
- Living With Multimorbidity: Care Coordination and Symptom Management Program (COORDINATE) (NA)
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- Exercise for the Treatment of Cancer-Related Sarcopenia (NA)
- Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR
- A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |